Unterzeichnung(en)
Übersicht
Pharmathen S.A.
The project concerns the promoter’s R&D activities from 2010 to 2013, related to the development of Active Pharmaceutical Ingredients (API) for generic pharmaceuticals, including new manufacturing processes.
The project objectives are to enlarge the company’s generic product offering and develop new drug delivery techniques for originator drugs approaching patent expiry, with the aim of extending protection from generic competition through life-cycle management. Apart from research and development, the project also comprises regulatory approval processes.
The R&D activities encompassed within this project will not materially change current R&D practices and will be carried out within existing facilities making use of existing laboratories, pilot plants, clinical centres etc. Thus an Environmental Impact Assessment (EIA) according to the EU Directive 97/11, as amended by Directive 2003/35, is not required.
The promoter is a private company not operating in the Utilities sector, and is thus not covered by EU Directives on procurement. Procedures followed will be verified during appraisal.
Loan foreseen under the Risk Sharing Finance Facility (RSFF).